Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer

Autor:	Mahesh Padval, Anne Poli, Suzanne F. Jones, Howard A. Burris, Kathleen N. Moore, Mitchell Keegan, Manish R. Patel, Joanna Horobin, Jeffrey R. Infante
Rok vydání:	2014
Předmět:	Cancer Research Advanced ovarian cancer business.industry Weekly paclitaxel Tumor cells medicine.disease Metastasis Blockade Focal adhesion Oncology Defactinib Immunology Cancer research Medicine Tumor growth biological phenomena cell phenomena and immunity business
Zdroj:	Journal of Clinical Oncology. 32:5521-5521
ISSN:	1527-7755 0732-183X
Popis:	5521 Background: Defactinib (VS-6063) is an oral inhibitor of focal adhesion kinase (FAK). Blockade of FAK has been shown to reduce tumor growth and metastasis through inhibition of tumor cell surv...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0ca2aa72d4a79e9c407fe16abf241952 https://doi.org/10.1200/jco.2014.32.15_suppl.5521 Zobrazit plný text záznamu